Bit2Me Group introduced Bit2Shield, a unit designed to assist public authorities and financial institutions in tracing cryptocurrency linked to investigations, securing seized assets, and preparing forensic reports for court use. The unit offers services such as on-chain tracing, technical support during seizures, custody, source-of-funds checks, and training. Bit2Shield managed over €1.5 million in seized crypto assets in 2025 through joint operations with Interpol and Europol. Assets are held in isolated multisignature cold wallets, with liquidation coordinated by Bit2Shield and conversion to euros handled by Bitcoinforme, authorized by Spain's CNMV to provide crypto-asset services from October 2025.
Bit2Me’s Bit2Shield crypto seizure and forensics services are the subject here, with Pluang market data providing context. For readers following major cryptocurrencies, 5 rose and 43 fell out of 50 priced assets on Pluang. Notable movers include BAT at Rp2.878 with a 1-day change of -9.83%, EOS at Rp12.649 up 8.13%, and EGLD at Rp60.783 down 7.38%, as of Oct 24, 2026 20:01 WIB.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
